{"id":112086,"date":"2008-05-22T12:46:02","date_gmt":"2008-05-22T16:46:02","guid":{"rendered":"https:\/\/www.send2press.com\/wire\/targeted-gene-delivery-in-vivo-rexin-g-monotherapy-reveals-significant-biological-activity-without-toxicity-in-chemo-resistant-metastatic-breast-cancer-asco-2008\/"},"modified":"2008-05-22T12:46:02","modified_gmt":"2008-05-22T16:46:02","slug":"targeted-gene-delivery-in-vivo-rexin-g-monotherapy-reveals-significant-biological-activity-without-toxicity-in-chemo-resistant-metastatic-breast-cancer-asco-2008","status":"publish","type":"post","link":"https:\/\/www.send2press.com\/wire\/targeted-gene-delivery-in-vivo-rexin-g-monotherapy-reveals-significant-biological-activity-without-toxicity-in-chemo-resistant-metastatic-breast-cancer-asco-2008\/","title":{"rendered":"TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)"},"content":{"rendered":"

NEWS SOURCE: Epeius Biotechnologies Corporation<\/strong><\/p>\n

SAN MARINO, Calif., May 22 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I\/II study of Rexin-G(R) for metastatic breast cancer that is refractory to conventional chemotherapy (J Clin Oncol 26:14509, 2008). This clinical trial employed intra-patient dose-escalations of Rexin-G given i.v. two to three times a week for 4 weeks, with doses ranging from 2 x 10e11 cfu to 6 x 10e11 cfu per week. The goal of the adaptive trial design is to confirm the over-all safety of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II pivotal study. <\/p>\n

\"Caption:The interim results of this Phase I\/II study of targeted gene delivery in vivo are very encouraging-intravenous infusions of Rexin-G demonstrated significant biological activity without toxicity in patients with rapidly progressive chemo-resistant breast cancer. Once the general safety of repeated infusions of Rexin-G was documented, the FDA approved across the board intra-patient dose-escalations in order to gain better tumor control. <\/p>\n

These escalating doses of Rexin-G were associated with stabilization of disease, using both RECIST and International PET criteria, significant reductions in CA 15.3 levels, a median progression-free survival of 6 months (RECIST) and a median over-all survival of greater than 7 months with all patients surviving at the 8-month follow-up period. No dose-limiting toxicity was observed, even at the higher doses of Rexin-G, thus confirming that repeated infusions of Rexin-G are safe and well-tolerated. <\/p>\n

According to Dr. Erlinda M. Gordon, Medical Director of Epeius, “The importance of these dose-escalation studies-which clearly establish safety before escalating to more potent tumoricidal levels-is a primary concern in the development of a new genetic medicine like Rexin-G.” <\/p>\n

Taken together with the results of previous studies, the current on-going Phase I\/II study confirms the exemplary safety and therapeutic potential of Rexin-G in chemotherapy-resistant metastatic breast cancer. <\/p>\n

For more information about Rexin-G, on-going clinical trials in the USA and abroad, and\/or Epeius pathotropic (disease-seeking) gene delivery systems, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.<\/p>\n

Epeius Biotechnologies: www.epeiusbiotech.com<\/a>.<\/p>\n

Rexin-G is a reg. trademark. <\/p>\n

News issued by: Epeius Biotechnologies Corporation<\/p>\n

\"Epeius<\/p>\n

Original Image: https:\/\/www.send2press.com\/wire\/images\/08-0421-Epeius_72dpi.jpg<\/a><\/small><\/p>\n

# # # <\/p>\n

Original Story ID: (4001) :: 2008-05-0522-001<\/small><\/p>\n

Original Keywords: Epeius Biotechnologies Corporation, Rexin-G for metastatic breast cancer, pathotropic disease-seeking gene delivery systems, Dr. Erlinda M. Gordon, ASCO 2008, refractory to conventional chemotherapy, RECIST and International PET criteria Epeius Biotechnologies Corporation <\/small><\/p>\n

NEWS SOURCE: Epeius Biotechnologies Corporation<\/strong> | Published: 2008-05-22 12:46:02<\/p>\n","protected":false},"excerpt":{"rendered":"

SAN MARINO, Calif., May 22 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I\/II study of Rexin-G for metastatic breast cancer that is refractory to conventional chemotherapy (J Clin Oncol 26:14509, 2008). This clinical trial employed intra-patient dose-escalations of Rexin-G given i.v. two to three times a week for 4 weeks, with doses ranging from 2 x 10e11 cfu to 6 x 10e11 cfu per week.<\/p>\n","protected":false},"author":9780,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"singles-wide.php","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[19937],"tags":[],"class_list":["post-112086","post","type-post","status-publish","format-standard","hentry","category-press-releases-archive","has-post-title","has-post-date","no-post-category","no-post-tag","no-post-comment","has-post-author"],"acf":[],"views":446,"_links":{"self":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/112086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/users\/9780"}],"replies":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/comments?post=112086"}],"version-history":[{"count":0,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/112086\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media?parent=112086"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/categories?post=112086"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/tags?post=112086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}